FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387033262> ?p ?o ?g. }

• W4387033262 abstract "The current therapeutic challenges for treating fungal diseases demand new approaches and new drugs. A promising strategy involves combination therapy with agents of distinct mechanisms of action to increase fungicidal activity and limit the impact of mutations leading to resistance. In this study, we evaluated the antifungal potential of bortezomib by examining the inhibition of proteasome activity, cell proliferation, and capsule production by Cryptococcus neoformans, the causative agent of fungal meningoencephalitis. Chemical genetic screens with collections of deletion mutants identified potential druggable targets for combination therapy with bortezomib. In vitro assays of combinations of bortezomib with flucytosine, chlorpromazine, bafilomycin A1, copper sulfate, or hydroxyurea revealed antifungal effects against C. neoformans. Furthermore, combination treatment with bortezomib and flucytosine in a murine inhalation model of cryptococcosis resulted in the improvement of neurological functions and reduced fungal replication and dissemination, leading to a delay in disease progression. This study therefore highlights the utility of chemical genetic screens to identify new therapeutic approaches as well as the antifungal potential of proteasome inhibition. IMPORTANCE Fungal diseases of humans are difficult to treat, and there is a clear need for additional antifungal drugs, better diagnostics, effective vaccines, and new approaches to deal with emerging drug resistance. Fungi are challenging to control because they share many common biochemical functions with their mammalian hosts and it is therefore difficult to identify fungal-specific targets for drug development. One approach is to employ existing antifungal drugs in combination with agents that target common cellular processes at levels that are (ideally) not toxic for the host. We pursued this approach in this study by examining the potential of the clinically approved proteasome inhibitor bortezomib to influence the proliferation and virulence of Cryptococcus neoformans. We found that the combination of bortezomib with the anti-cryptococcal drug flucytosine improved the survival of infected mice, thus demonstrating the potential of this strategy for antifungal therapy." @default.
• W4387033262 created "2023-09-27" @default.
• W4387033262 creator A5005880397 @default.
• W4387033262 creator A5011945881 @default.
• W4387033262 creator A5015429289 @default.
• W4387033262 creator A5033642835 @default.
• W4387033262 creator A5081248896 @default.
• W4387033262 creator A5092939468 @default.
• W4387033262 date "2023-09-26" @default.
• W4387033262 modified "2023-09-27" @default.
• W4387033262 title "Proteasome inhibition as a therapeutic target for the fungal pathogen <i>Cryptococcus neoformans</i>" @default.
• W4387033262 cites W1550693054 @default.
• W4387033262 cites W1551144904 @default.
• W4387033262 cites W1604457040 @default.
• W4387033262 cites W1741662749 @default.
• W4387033262 cites W1814010719 @default.
• W4387033262 cites W1915040721 @default.
• W4387033262 cites W1929821956 @default.
• W4387033262 cites W1970175970 @default.
• W4387033262 cites W1976914087 @default.
• W4387033262 cites W1981239770 @default.
• W4387033262 cites W1999042605 @default.
• W4387033262 cites W2000874885 @default.
• W4387033262 cites W2002155770 @default.
• W4387033262 cites W2007703161 @default.
• W4387033262 cites W2013666305 @default.
• W4387033262 cites W2077588719 @default.
• W4387033262 cites W2088245562 @default.
• W4387033262 cites W2094032599 @default.
• W4387033262 cites W2096855445 @default.
• W4387033262 cites W2099951777 @default.
• W4387033262 cites W2104411181 @default.
• W4387033262 cites W2108279225 @default.
• W4387033262 cites W2108675611 @default.
• W4387033262 cites W2111094455 @default.
• W4387033262 cites W2112064435 @default.
• W4387033262 cites W2113522006 @default.
• W4387033262 cites W2115218373 @default.
• W4387033262 cites W2116536284 @default.
• W4387033262 cites W2117206304 @default.
• W4387033262 cites W2118523249 @default.
• W4387033262 cites W2119849409 @default.
• W4387033262 cites W2121199243 @default.
• W4387033262 cites W2126076750 @default.
• W4387033262 cites W2129431352 @default.
• W4387033262 cites W2133750516 @default.
• W4387033262 cites W2135177684 @default.
• W4387033262 cites W2142269012 @default.
• W4387033262 cites W2144543496 @default.
• W4387033262 cites W2149579582 @default.
• W4387033262 cites W2164391886 @default.
• W4387033262 cites W2167737387 @default.
• W4387033262 cites W2228945562 @default.
• W4387033262 cites W2238545098 @default.
• W4387033262 cites W2256548132 @default.
• W4387033262 cites W2278506590 @default.
• W4387033262 cites W2301515547 @default.
• W4387033262 cites W2318477319 @default.
• W4387033262 cites W2415657445 @default.
• W4387033262 cites W2478575915 @default.
• W4387033262 cites W2484263890 @default.
• W4387033262 cites W2509038340 @default.
• W4387033262 cites W2580614520 @default.
• W4387033262 cites W2606931784 @default.
• W4387033262 cites W2608385659 @default.
• W4387033262 cites W2608596682 @default.
• W4387033262 cites W2611697423 @default.
• W4387033262 cites W2704320285 @default.
• W4387033262 cites W2744284720 @default.
• W4387033262 cites W2751554926 @default.
• W4387033262 cites W2756943820 @default.
• W4387033262 cites W2784802165 @default.
• W4387033262 cites W2795686900 @default.
• W4387033262 cites W2798011605 @default.
• W4387033262 cites W2800101762 @default.
• W4387033262 cites W2890646686 @default.
• W4387033262 cites W2915517175 @default.
• W4387033262 cites W3008971975 @default.
• W4387033262 cites W3127236674 @default.
• W4387033262 cites W3146780943 @default.
• W4387033262 cites W3156351468 @default.
• W4387033262 cites W4225910596 @default.
• W4387033262 doi "https://doi.org/10.1128/spectrum.01904-23" @default.
• W4387033262 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37750732" @default.
• W4387033262 hasPublicationYear "2023" @default.
• W4387033262 type Work @default.
• W4387033262 citedByCount "0" @default.
• W4387033262 crossrefType "journal-article" @default.
• W4387033262 hasAuthorship W4387033262A5005880397 @default.
• W4387033262 hasAuthorship W4387033262A5011945881 @default.
• W4387033262 hasAuthorship W4387033262A5015429289 @default.
• W4387033262 hasAuthorship W4387033262A5033642835 @default.
• W4387033262 hasAuthorship W4387033262A5081248896 @default.
• W4387033262 hasAuthorship W4387033262A5092939468 @default.
• W4387033262 hasBestOaLocation W43870332621 @default.
• W4387033262 hasConcept C203014093 @default.
• W4387033262 hasConcept C27740335 @default.
• W4387033262 hasConcept C2776364478 @default.
• W4387033262 hasConcept C2777328456 @default.
• W4387033262 hasConcept C2777478702 @default.

• next